NEW YORK - IN8bio, Inc. (Nasdaq: INAB), a biopharmaceutical company specializing in gamma-delta T cell therapies with a current market capitalization of $23.42 million, has announced encouraging Phase ...
Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies,” published in the February 2025 issue of American Journal of Hematology by Senapati et ...
The Standard-Times on MSN2d
New Bedford family of toddler fighting leukemia gets support from Cops for Kids with CancerCops for Kids with Cancer seeks to remove the financial burden for families impacted by a cancer diagnosis. This week they ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...
IN8bio is accelerating patient enrollment in the INB-100 program and expects to complete enrollment of the expansion cohort in 2025. The company’s FDA discussions confirmed that relapse-free survival ...
Immune cells in the bone marrow microenvironment of AML patients are key in distinguishing a response to immunotherapy.
If Maggie O'Neil can't find a match among family members, she'll have to turn to a global nonprofit that connects volunteer ...
Aptose Biosciences (NASDAQ:APTO;TSX:APS), a clinical-stage oncology stock, achieved positive safety and response results from ...
Study Progresses to Fourth Higher 90 mg/m2Dose CohortCompelling Patient Response Highlighted by Stable Disease and Significant Reduction in Blast ...
IN8bio has announced encouraging new clinical data from its ongoing Phase I trial of INB-100, an allogeneic gamma-delta T ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback